Media, investors, advocacy organizations and others, please contact us here.

IgA Nephropathy: Current Treatment Landscape,
Disease Burden, and 2-Year PROTECT Trial Data Supporting Sparsentan as an Emerging Treatment Option

In this podcast, Dr. Edgar Lerma and Dr. Dana Rizk discuss IgA nephropathy
and the key data on sparsentan from the phase 3 PROTECT trial.

Also find us on: Apple PodcastsApple Podcasts SpotifySpotify

  • The disease burden and underlying pathophysiology of IgA nephropathy, including the role of endothelin and angiotensin in disease progression
  • The current IgAN treatment landscape
  • The response to sparsentan, a dual endothelin angiotensin receptor antagonist, in patients with IgA nephropathy in the phase 3 PROTECT trial

MA-SP-24-0017